UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial

JAMA neurology, 2021-05, Vol.78 (5), p.558

2021

Volltextzugriff (PDF)

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

Lancet neurology, 2019-11, Vol.18 (11), p.1009-1020

2019

Volltextzugriff (PDF)

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

Lancet neurology, 2019-11, Vol.18 (11), p.1021-1033

2019

Volltextzugriff (PDF)

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

Multiple Sclerosis Journal, 2017-08, Vol.23 (9), p.1179-1187

2017

Volltextzugriff (PDF)

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study

Journal of neurology, 2016-07, Vol.263 (7), p.1287-1295

2016

Volltextzugriff (PDF)

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement

Journal of neuroimmunology, 2021-08, Vol.357, p.577627-577627, Article 577627

2021

Volltextzugriff (PDF)

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Multiple sclerosis, 2022-10, Vol.28 (12), p.1944-1962

2022

Volltextzugriff (PDF)

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

Multiple sclerosis, 2019-08, Vol.25 (9), p.1255-1262

2019

Volltextzugriff (PDF)

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis

Journal of neurology, 2022-03, Vol.269 (3), p.1670-1677

2022

Volltextzugriff (PDF)

Thalamic atrophy is associated with development of clinically definite multiple sclerosis

Radiology, 2013-09, Vol.268 (3), p.831-841

2013

Volltextzugriff (PDF)

Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Yes

Multiple sclerosis, 2012-09, Vol.18 (9), p.1209-1210

HAVRDOVA, Eva

2012

Volltextzugriff (PDF)

The potential of serum neurofilament as biomarker for multiple sclerosis

Brain (London, England : 1878), 2021-11, Vol.144 (10), p.2954-2963

2021

Volltextzugriff (PDF)

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis

Multiple sclerosis, 2019-08, Vol.25 (9), p.1273-1288

2019

Volltextzugriff (PDF)

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

Multiple sclerosis, 2021-03, Vol.27 (3), p.479-482

2021

Volltextzugriff (PDF)

Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group

Multiple sclerosis and related disorders, 2015-05, Vol.4 (3), p.202-218

2015

Volltextzugriff (PDF)

Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients

BMC neurology, 2017-07, Vol.17 (1), p.145-145, Article 145

2017

Volltextzugriff (PDF)

Real-Life Outcome in Multiple Sclerosis in the Czech Republic

Multiple sclerosis international, 2019-01, Vol.2019 (2019), p.1-8

2019

Volltextzugriff (PDF)

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease

Therapeutic Advances in Neurological Disorders, 2020, Vol.13, p.1756286420975223-1756286420975223

2020

Volltextzugriff (PDF)

Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis

Annals of neurology, 2008-05, Vol.63 (5), p.611-620

2008

Volltextzugriff (PDF)

Management of multiple sclerosis patients in central European countries: current needs and potential solutions

Therapeutic Advances in Neurological Disorders, 2018-01, Vol.11, p.1756286418759189-1756286418759189

2018

Volltextzugriff (PDF)

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE

Multiple sclerosis, 2018-12, Vol.24 (14), p.1883-1891

2018

Volltextzugriff (PDF)

Flow Cytometry Analysis of Blood Large Extracellular Vesicles in Patients with Multiple Sclerosis Experiencing Relapse of the Disease

Journal of clinical medicine, 2022-05, Vol.11 (10), p.2832

2022

Volltextzugriff (PDF)

Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial

Multiple sclerosis and related disorders, 2016-03, Vol.6, p.66-72

2016

Volltextzugriff (PDF)

Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists

Multiple sclerosis and related disorders, 2022-01, Vol.57, p.103389-103389, Article 103389

2022

Volltextzugriff (PDF)

1 – 25 von 493

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(456)
Mit Volltextzugriff
(285)

Publikationsform

Artikel
(491)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(273)
Life Sciences & Biomedicine
(267)
Neurosciences & Neurology
(226)
Multiple Sclerosis
(222)
Clinical Neurology
(202)
Humans
(187)
Neurosciences
(127)
Female
(126)
Adult
(116)
Male
(115)
Middle Aged
(82)
Neurology
(80)
Magnetic Resonance Imaging
(72)
Multiple Sclerosis, Relapsing-Remitting - Drug Therapy
(70)
Disease Progression
(55)
Multiple Sclerosis - Drug Therapy
(54)
Patients
(50)
Treatment Outcome
(46)
Interferon
(36)
Young Adult
(36)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Neurology
(161)
Multiple Sclerosis
(49)
Multiple Sclerosis And Related Disorders
(32)
Journal Of Neurology, Neurosurgery And Psychiatry
(24)
Journal Of Neurology
(17)
Lancet Neurology
(15)
European Journal Of Neurology
(12)
Brain
(8)
Jama Neurology
(8)
Archives Of Neurology
(7)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial

Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial

“No evident disease activity”: The use of combined assessments in the management of patients with multiple sclerosis

Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study

Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis

Thalamic atrophy is associated with development of clinically definite multiple sclerosis

Industrial pharmaceutical drug research has done more for the health of people with MS than academic neurologists: Yes

The potential of serum neurofilament as biomarker for multiple sclerosis

Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis

The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges

Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group

Peripheral blood lymphocytes immunophenotyping predicts disease activity in clinically isolated syndrome patients

Real-Life Outcome in Multiple Sclerosis in the Czech Republic

Factors influencing daily treatment choices in multiple sclerosis: practice guidelines, biomarkers and burden of disease

Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis

Management of multiple sclerosis patients in central European countries: current needs and potential solutions

Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE

Flow Cytometry Analysis of Blood Large Extracellular Vesicles in Patients with Multiple Sclerosis Experiencing Relapse of the Disease

Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study

Effect of desire for pregnancy on decisions to escalate treatment in multiple sclerosis care: Differences between MS specialists and non-MS specialists

Suchergebnisse filtern